The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Valvular Heart Disease and the Use of Dopamine Agonists for Parkinson's Disease
Open accessAbstract
BACKGROUND: Ergot-derived dopamine receptor agonists, often used in the treatment of Parkinson's disease, have been associated with an increased risk of valvular heart disease. METHODS: We performed an echocardiographic prevalence study in 155 patients taking dopamine agonists for Parkinson's disease (pergolide, 64 patients; cabergoline, 49; and non-ergot-derived dopamine agonists, 42) and 90 control subjects. Valve regurgitation was assessed according to American Society of Echocardiography recommendations. The mitral-valve tenting area was also measured and used as a quantitative index for leaflet stiffening and apical displacement of leaflet coaptation. RESULTS: Clinically important regurgitation (moderate to severe, grade 3 to 4) in any valve was found with significantly greater frequency in patients taking pergolide (23.4%) or cabergoline (28.6%) but not in patients taking non-ergot-derived dopamine agonists (0%), as compared with control subjects (5.6%). The relative risk for moderate or severe valve regurgitation in the pergolide group was 6.3 for mitral regurgitation (P=0.008), 4.2 for aortic regurgitation (P=0.01), and 5.6 for tricuspid regurgitation (P=0.16); corresponding relative risks in the cabergoline group were 4.6 (P=0.09), 7.3 (P<0.001), and 5.5 (P=0.12). The mean mitral tenting area was significantly greater in ergot-treated patients and showed a linear relationship with the severity of mitral regurgitation. Patients treated with ergot derivatives who had grade 3 to 4 regurgitation of any valve had received a significantly higher mean cumulative dose of pergolide or cabergoline than had patients with lower grades. CONCLUSIONS: The frequency of clinically important valve regurgitation was significantly increased in patients taking pergolide or cabergoline, but not in patients taking non-ergot-derived dopamine agonists, as compared with control subjects. These findings should be considered in evaluating the risk-benefit ratio of treatment with ergot derivatives.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zoghbi, W. A., Enriquez-Sarano, M., Foster, E., Grayburn, P. A., Kraft, C. D., Levine, R. A., Nihoyannopoulos, P., Otto, C. M., Quinones, M. A., Rakowski, H., et al. (2003) · Journal of the American Society of Echocardiography · doi:10.1016/s0894-7317(03)00335-3 · Cited by 4,044
Yock, P. G., & Popp, R. L. (1984) · Circulation · doi:10.1161/01.cir.70.4.657 · Cited by 1,640
Rothman, R. B., Baumann, M. H., Savage, J. E., Rauser, L., McBride, A., Hufeisen, S. J., & Roth, B. L. (2000) · Circulation · doi:10.1161/01.cir.102.23.2836 · Cited by 722
Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease
Van Camp, G., Flamez, A., Cosyns, B., Weytjens, C., Muyldermans, L., Van Zandijcke, M., De Sutter, J., Santens, P., Decoodt, P., Moerman, C., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15945-x · Cited by 321
Severe multivalvular heart disease: A new complication of the ergot derivative dopamine agonists
Horvath, J., Fross, R. D., Kleiner‐Fisman, G., Lerch, R., Stalder, H., Liaudat, S., Raskoff, W. J., Flachsbart, K. D., Rakowski, H., Pache, J., et al. (2004) · Movement Disorders · doi:10.1002/mds.20201 · Cited by 243
Valve Disease Associated with Ergot Alkaloid Use: Echocardiographic and Pathologic Correlations
Redfield, M. M., Nicholson, W. J., Edwards, W. D., & Tajik, A. J. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-1-50 · Cited by 154
Pergolide use in Parkinson disease is associated with cardiac valve regurgitation
Baseman, D., O’Suilleabhain, P. E., Reimold, S. C., Laskar, S. R., Baseman, J. G., & Dewey, R. B. (2004) · Neurology · doi:10.1212/01.wnl.0000129842.49926.07 · Cited by 119
Heart valvular disease in patients with Parkinson’s disease treated with high-dose pergolide
Camp, G. V., Flamez, A., Cosyns, B., Goldstein, J. W., Perdaens, C., & Schoors, D. (2003) · Neurology · doi:10.1212/01.wnl.0000083985.00343.f2 · Cited by 115
Agonism at 5-HT2B receptors is not a class effect of the ergolines
Jähnichen, S., HOROWSKI, R., & Pertz, H. H. (2005) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.03.010 · Cited by 106
Fibrotic Valvular Heart Disease Subsequent to Bromocriptine Treatment
Serratrice, J., DISDIER, P., Habib, G., Viallet, F., & Weiller, P. (2002) · Cardiology in Review · doi:10.1097/00045415-200211000-00005 · Cited by 106
Jollis, J. G., Landolfo, C. K., KISSLO, J. A., Constantine, G. D., Davis, K. D., & Ryan, T. (2000) · Circulation · doi:10.1161/01.cir.101.17.2071 · Cited by 100
Cabergoline-Related Severe Restrictive Mitral Regurgitation
Pinero, A., Marcos‐Alberca, P., & Fortes, J. (2005) · New England Journal of Medicine · doi:10.1056/nejm200511033531822 · Cited by 98
Prevalence and Determinants of Valvulopathy in Patients Treated With Dexfenfluramine
Shively, B. K., Roldan, C. A., Gill, E. A., Najarian, T., & Loar, S. B. (1999) · Circulation · doi:10.1161/01.cir.100.21.2161 · Cited by 81
Rascol, O., Pathak, A., Bagheri, H., & Montastruc, J. (2004) · Movement Disorders · doi:10.1002/mds.20202 · Cited by 42
Cited by
The expanded biology of serotonin
Berger, M., Gray, J. A., & Roth, B. L. (2009) · Annual Review of Medicine · doi:10.1146/annurev.med.60.042307.110802 · Cited by 2,100
Diagnosis and treatment of hyperprolactinemia: an Endocrine Society Clinical Practice Guideline
Melmed, S., Casanueva, F. F., Hoffman, A. R., Kleinberg, D. L., Montori, V. M., Schlechte, J. A., & Wass, J. A. H. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1692 · Cited by 1,844
Clinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (MEN1)
Thakker, R. V., Newey, P. J., Walls, G. V., Bilezikian, J., Dralle, H., Ebeling, P. R., Melmed, S., Sakurai, A., Tonelli, F., & Brandi, M. L. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1230 · Cited by 1,477
Francis, G. L., Waguespack, S. G., Bauer, A. J., Angelos, P., Benvenga, S., Cerutti, J. M., Dinauer, C. A., Hamilton, J., Hay, I. D., Luster, M., et al. (2015) · Thyroid · doi:10.1089/thy.2014.0460 · Cited by 1,238
Ramage, J. K., Ahmed, A., Ardill, J., Bax, N., Breen, D. J., Caplin, M. E., Corrie, P., Davar, J., Davies, A. H., Lewington, V, et al. (2012) · Gut · doi:10.1136/gutjnl-2011-300831 · Cited by 952
Metadata
- Authors
- Zanettini, R., Antonini, A., Gatto, G., Gentile, R., Tesei, S., & Pezzoli, G.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-01-04
- Volume
- 356
- Issue
- 1
- Pages
- 39-46
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2079846716
- Cited by
- 884
- References
- 14
- FWCI
- 68.39
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.